About this Research Topic
The advent of immunotherapy has revolutionized the landscape of cancer treatment, bringing new hope to patients suffering from various types of tumors. Despite its transformative impact, a substantial number of patients eventually develop resistance, which significantly reduces the overall efficacy of these therapies. Emerging research underscores the pivotal roles that metabolic reprogramming and epigenetic modifications play in sculpting the tumor microenvironment, thereby impeding the immune system’s ability to effectively recognize and eliminate cancer cells.
Metabolic alterations within cancer cells, such as shifts in glucose and lipid metabolism, generate conditions that facilitate immune evasion. In parallel, epigenetic changes, including DNA methylation and histone modifications, further exacerbate this resistance by altering the expression of crucial immune-related genes. These dual processes create a hostile environment for immune interventions. Understanding the complex interplay between metabolic and epigenetic mechanisms is vital for identifying new therapeutic targets that can overcome resistance, offering the potential to enhance patient outcomes and the overall success of immunotherapies.
The primary goal of this Research Topic is to bring together cutting-edge studies that explore how metabolism and epigenetic regulation contribute to tumor resistance against immunotherapy. We aim to uncover novel insights into potential biomarkers and therapeutic strategies to address these challenges.
We invite researchers to submit original research articles, comprehensive reviews, and short communications that delve into, but are not limited to, the following themes:
1. The role of metabolic reprogramming within the tumor microenvironment and its contribution to immunotherapy resistance.
2. Epigenetic modifications and their influence on immune evasion and tumor response to treatment.
3. Cross-talk between metabolic and epigenetic pathways in tumors and how this interaction contributes to resistance.
4. Development of novel therapeutic interventions targeting both metabolic and epigenetic pathways to circumvent resistance.
5. Clinical studies and translational research focused on identifying metabolic and epigenetic biomarkers associated with immunotherapy resistance.
Metabolic alterations within cancer cells, such as shifts in glucose and lipid metabolism, generate conditions that facilitate immune evasion. In parallel, epigenetic changes, including DNA methylation and histone modifications, further exacerbate this resistance by altering the expression of crucial immune-related genes. These dual processes create a hostile environment for immune interventions. Understanding the complex interplay between metabolic and epigenetic mechanisms is vital for identifying new therapeutic targets that can overcome resistance, offering the potential to enhance patient outcomes and the overall success of immunotherapies.
The primary goal of this Research Topic is to bring together cutting-edge studies that explore how metabolism and epigenetic regulation contribute to tumor resistance against immunotherapy. We aim to uncover novel insights into potential biomarkers and therapeutic strategies to address these challenges.
We invite researchers to submit original research articles, comprehensive reviews, and short communications that delve into, but are not limited to, the following themes:
1. The role of metabolic reprogramming within the tumor microenvironment and its contribution to immunotherapy resistance.
2. Epigenetic modifications and their influence on immune evasion and tumor response to treatment.
3. Cross-talk between metabolic and epigenetic pathways in tumors and how this interaction contributes to resistance.
4. Development of novel therapeutic interventions targeting both metabolic and epigenetic pathways to circumvent resistance.
5. Clinical studies and translational research focused on identifying metabolic and epigenetic biomarkers associated with immunotherapy resistance.
Keywords: Immunotherapy resistance, Metabolic reprogramming, Epigenetic modifications, Tumor microenvironment, Therapeutic interventions
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
